These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 29195616

  • 1. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S, Shah H, Jacene H.
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [Abstract] [Full Text] [Related]

  • 2. PET/CT: Clinical role in lymphomas.
    Papathanasiou N.
    Hell J Nucl Med; 2023 Jan; 26 Suppl():36-37. PubMed ID: 37658560
    [Abstract] [Full Text] [Related]

  • 3. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD.
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
    Thanarajasingam G, Bennani-Baiti N, Thompson CA.
    Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
    [Abstract] [Full Text] [Related]

  • 7. FDG-PET/CT in the management of lymphomas: current status and future directions.
    El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY.
    J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET/CT in the clinical management of patients with lymphoma.
    Tamayo P, Martín A, Díaz L, Cabrero M, García R, García-Talavera P, Caballero D.
    Rev Esp Med Nucl Imagen Mol; 2017 Oct; 36(5):312-321. PubMed ID: 28483374
    [Abstract] [Full Text] [Related]

  • 9. PET/CT for Staging; Past, Present, and Future.
    El-Galaly TC, Gormsen LC, Hutchings M.
    Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
    [Abstract] [Full Text] [Related]

  • 10. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T.
    Rinsho Ketsueki; 2016 Jan; 57(10):2008-2012. PubMed ID: 27795508
    [Abstract] [Full Text] [Related]

  • 11. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
    Prieto Prieto JC, Vallejo Casas JA, Hatzimichael E, Fotopoulos A, Kiortsis DN, Sioka C.
    Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
    [Abstract] [Full Text] [Related]

  • 12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.
    Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA.
    Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
    [Abstract] [Full Text] [Related]

  • 13. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
    Al Tabaa Y, Tchernonog E, Faurie P, Cottereau AS, Monjanel H, Bonnet A, Le Gouill S, Gyan E, Ghesquieres H, Mariano-Goulart D, Cartron G.
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F, Alongi P, Incerti E, Gianolli L, Picchio M, Kayani I, Bomanji J.
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [Abstract] [Full Text] [Related]

  • 15. Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma.
    Kim J, Lee JO, Paik JH, Lee WW, Kim SE, Song YS.
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W, Zhao J, Wang C, Wang T, Xing Y.
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [Abstract] [Full Text] [Related]

  • 18. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N, Delgado-Bolton RC, Del Campo Del Val L, Cabezas B, Arranz R, García M, Cannata J, González Ortega S, Pérez Sáez MÁ, López-Botet B, Rodríguez-Vigil B, Mateo M, Colletti PM, Rubello D, Carreras JL.
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [Abstract] [Full Text] [Related]

  • 19. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C, Minoia C, Asabella AN, Nicoletti A, Altini C, Antonica F, Ficco M, Guarini A, Maggialetti N, Rubini G.
    Hell J Nucl Med; 2014 Aug; 17 Suppl 1():40-9. PubMed ID: 24392468
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A.
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.